All In Biotech

Drug Trial Radar · NCT00442936

Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Response to a Single Treatment With Oral MK0974 With Placebo and Comparator in Subjects With Moderate to Severe Acute Migraine With or Without Aura

Last checked: Nov 20, 2026Latest source record: Oct 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,380 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,380

Actual

Start

Feb 15, 2007

Primary completion

Oct 2, 2007

Study completion Oct 2, 2007

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the efficacy and safety of telcagepant (MK-0974) compared to an approved medication for acute migraine. This study was conducted as a "triple-dummy" design; for each dose of study drug, participants each received 3 forms of study drug (2 capsules of active and/or placebo and 1 tablet of active and/or placebo) and were instructed to take one of each form of study drug at dosing time. The primary hypotheses of this study are that telcagepant is superior to placebo in Pain Freedom at 2 Hours Post-Dose, Pain Relief at 2 Hours Post-Dose, Absence of Photophobia at 2 Hours Post-Dose, Absence of Phonophobia at 2 Hours Post-Dose and Absence of Nausea at 2 Hours Post-Dose.

Conditions

  • Migraine

Interventions

  • Telcagepant potassium 150 mgDrug

    Telcagepant 150 mg liquid-filled soft gel capsules

  • Telcagepant potassium 300 mgDrug

    Telcagepant 300 mg liquid-filled soft gel capsules

  • Zolmitriptan 5 mgDrug

    Zolmitriptan 5 mg tablets

  • Placebo to telcagepant 150 mgDrug

    Placebo to match telcagepant 150 mg liquid-filled soft gel capsules

  • Placebo to tecagepant 300 mgDrug

    Placebo to match tecagepant 300 mg liquid-filled soft gel capsules

  • Placebo to zolmitriptan 5 mgDrug

    Placebo to match zolmitriptan 5 mg tablets

  • Rescue medicationDrug

    If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Pain Freedom (PF) at 2 Hours Post-DoseTime frame: 2 hours post-dose
  2. Number of Participants With Pain Relief (PR) at 2 Hours Post-DoseTime frame: 2 hours post-dose
  3. Number of Participants With Absence of Photophobia at 2 Hours Post-DoseTime frame: 2 hours post-dose
  4. Number of Participants With Absence of Phonophobia at 2 Hours Post-DoseTime frame: 2 hours post-dose
  5. Number of Participants With Absence of Nausea at 2 Hours Post-DoseTime frame: 2 hours post-dose
  6. Number of Participants Who Experience At Least One Adverse Event (AE)Time frame: Up to 14 days after last dose of study drug
  7. Number of Participants Who Discontinue Study Drug Due to an AETime frame: Up to 48 hours after first dose of study drug

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.